View:
Download DOC
Download PDF
Download XLS
SEC FORM 3 SEC Form 3
FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940 		 
OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response: 0.5
1. Name and Address of Reporting Person*
Bellon Christine
(Last) (First) (Middle)
C/O BEAM THERAPEUTICS INC.
238 MAIN STREET
(Street)
CAMBRIDGE MA 02142
(City) (State) (Zip)
2. Date of Event Requiring Statement (Month/Day/Year)
03/16/2023 		3. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]
4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Legal Officer
 5. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4) 2. Amount of Securities Beneficially Owned (Instr. 4) 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock 58,441(1)(2) D
Table II - Derivative Securities Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4) 2. Date Exercisable and Expiration Date (Month/Day/Year) 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) 6. Nature of Indirect Beneficial Ownership (Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) (3) 03/31/2031 Common Stock 23,959(4) 80.04 D
Stock Option (Right to Buy) (5) 01/31/2032 Common Stock 30,000 69.21 D
Stock Option (Right to Buy) (6) 01/31/2033 Common Stock 35,000 43.45 D
Stock Option (Right to Buy) (7) 05/16/2029 Common Stock 19,946(8) 7.22 D
Stock Option (Right to Buy) (9) 05/17/2029 Common Stock 19,405(10) 7.22 D
Stock Option (Right to Buy) (11) 08/31/2031 Common Stock 10,000 110.92 D
Stock Option (Right to Buy) (12) 12/30/2032 Common Stock 25,000 39.11 D
Explanation of Responses:
1. Includes 9,375, 3,750, 15,000 and 12,500 restricted stock units ("RSUs") granted to the Reporting Person under the Issuer's 2019 Equity Incentive Plan on March 31, 2021, September 30, 2021, March 31, 2022 and December 30, 2022, respectively.
2. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The March 31, 2021, September 30, 2021 and March 31, 2022 RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with the Issuer through each vesting date. The December 30, 2022 RSUs vest in three substantially equal installments on each of the first three anniversaries of the grant date, subject to the Reporting Person's continued service with the Issuer through each vesting date. The March 31, 2021 RSUs grant was originally for 12,500 RSUs of which 3,125 RSUs have already vested. The September 30, 2021 RSUs grant was originally for 5,000 RSUs of which 1,250 RSUs have already vested.
3. The option vests at a rate of 2.08% each month until the option is fully vested.
4. The option grant was originally for options to purchase 25,000 shares of the Issuer's common stock of which 1,041 have already been exercised.
5. The option vests at a rate of 2.08% each month until the option is fully vested.
6. The option vests at a rate of 2.08% each month thereafter until the option is fully vested.
7. The option vests as to 25% on the first anniversary of the vesting commencement date, May 16, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.
8. The option grant was originally for options to purchase 100,350 shares of the Issuer's common stock of which 80,404 have already been exercised.
9. The option vests as to 25% on the first anniversary of the vesting commencement date, May 17, 2020, and at a rate of 2.78% each month thereafter until the option is fully vested.
10. The option grant was originally for options to purchase 42,704 shares of the Issuer's common stock of which 23,299 have already been exercised.
11. The option vests at a rate of 2.08% each month thereafter until the option is fully vested.
12. The option vests at a rate of 2.78% each month until the option is fully vested.
Remarks:
Exhibit List: Exhibit 24 - Power of Attorney
By: /s/ Christine Bellon 03/27/2023
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
                           LIMITED POWER OF ATTORNEY

       The undersigned hereby constitutes and appoints John Evans, Terry-Ann
Burrell, and Jon Mahlowitz, and each of them individually, with full power of
substitution, as the undersigned's true and lawful attorney-in-fact to:

       (1)   prepare, execute in the undersigned's name and on the undersigned's
             behalf, and submit to the U.S. Securities and Exchange Commission
             (the "SEC") a Form ID, including amendments thereto, and any other
             documents necessary or appropriate to obtain codes and passwords
             enabling the undersigned to make electronic filings with the SEC
             of reports required by Section 16(a) of the Securities Exchange Act
             of 1934, as amended, or any rule or regulation of the SEC;

       (2)   execute for and on behalf of the undersigned, in the undersigned's
             capacity as officer and/or director of Beam Therapeutics Inc. (the
             "Company"), Forms 3, 4, 5 and any Schedules 13D or 13G in
             accordance with Section 16(a) of the Securities Exchange Act of
             1934, as amended, and the rules thereunder;

       (3)   do and perform any and all acts for and on behalf of the
             undersigned that may be necessary or desirable to complete and
             execute any such Form 3, 4, or 5 or Schedule 13D or 13G, complete
             and execute any amendment or amendments thereto, and timely file
             such form with the SEC and any stock exchange or similar authority;
             and

       (4)   take any other action of any type whatsoever in connection with the
             foregoing that, in the opinion of each such attorney-in-fact, may
             be of benefit to, in the best interest of, or legally required by,
             the undersigned, it being understood that the documents executed
             by each such attorney-in-fact on behalf of t undersigned pursuant
             to this Power of Attorney shall be in such form and shall contain
             such tms and conditions as each such attorney-in-fact may approve
             in each such attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsecessary, or
proper to be donen the exercise of any of the rights and powers herein granted,
as fullyallntents an purposes  the undersigned might or could do if personally
present, with full poweofubitution or vocation, hereby ratiing and confirming
all that each such attorney-in-fact, or each such aney--facs substitute or
substitute shall lawfully do or cause to be done by virtue of this power of
atrneanthe rits and powers herein ted. The undersigned acknowledges that each
foregoing attorney-inact, inerng i such cacity at request of thendersigned, are
not assuming, nor is the Compa assungany  the
ndersigned respoibities to comply
wh Section 16 of the Securities Exchange o1934as ameed.

     This Pow of Attorn shall remain in fullorce and effect until the
undersigned is no longer required to file Forms 3, 4, 5, and any Schedules 13D
or 13G with respect to the undersigned's holdings of and transactions in
securities issued by the Company, unless earlier revoked by the undersigned in a
signed writing delivered to each foregoing attorney-in-fact.

                  [Remainder of page intentionally left blank]











       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 22nd day of March, 2023



                                          /s/ Christine Bellon
                                          ----------------------
                                          Name: Christine Bellon


















































Signature Page to Limited Power of Attorney